UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

The lancet oncology, 2022-01, Vol.23 (1), p.91-103

2022

Link zum Volltext

Verfügbarkeit prüfen

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease

The New England journal of medicine, 2012-07, Vol.367 (2), p.135-145

2012

Link zum Volltext

Verfügbarkeit prüfen

Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation

Scientific reports, 2021-02, Vol.11 (1), p.3230-3230, Article 3230

2021

Link zum Volltext

Verfügbarkeit prüfen

Ezh2 phosphorylation state determines its capacity to maintain CD8 + T memory precursors for antitumor immunity

Nature communications, 2017-12, Vol.8 (1), p.2125-14, Article 2125

2017

Link zum Volltext

Verfügbarkeit prüfen

Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study

Journal of clinical oncology, 2021-06, Vol.39 (17), p.1878-1887

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis

Blood, 2017-02, Vol.129 (7), p.906-916

2017

Link zum Volltext

Verfügbarkeit prüfen

Post-transplant lymphoproliferative disorder after lung transplantation: A review of 35 cases

The Journal of heart and lung transplantation, 2012-03, Vol.31 (3), p.296-304

2012

Link zum Volltext

Verfügbarkeit prüfen

Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen–specific CD8+ T Cells After Allogeneic Stem Cell Transplantation

Clinical cancer research, 2009-08, Vol.15 (15), p.4944-4953

2009

Link zum Volltext

Verfügbarkeit prüfen

Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials

Biology of blood and marrow transplantation, 2018-06, Vol.24 (6), p.1274-1280

2018

Link zum Volltext

Verfügbarkeit prüfen

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation

Journal of clinical oncology, 2017-12, Vol.35 (36), p.4003-4011

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation

Journal of clinical oncology, 2021-07, Vol.39 (21), p.2397-2409

2021

Link zum Volltext

Verfügbarkeit prüfen

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

The Lancet. Haematology, 2019-03, Vol.6 (3), p.e132-e143

2019

Link zum Volltext

Verfügbarkeit prüfen

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Journal of clinical oncology, 2016-06, Vol.34 (16), p.1864-1871

2016

Link zum Volltext

Verfügbarkeit prüfen

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning

Journal of clinical oncology, 2015-07, Vol.33 (21), p.2392-2398

2015

Link zum Volltext

Verfügbarkeit prüfen

Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients

Journal of antimicrobial chemotherapy, 2015-07, Vol.70 (7), p.2078-2083

2015

Link zum Volltext

Verfügbarkeit prüfen

Pilot Study of Prophylactic Ex Vivo Costimulated Donor Leukocyte Infusion After Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation

Biology of blood and marrow transplantation, 2013-07, Vol.19 (7), p.1094-1101

2013

Link zum Volltext

Verfügbarkeit prüfen

Plasmacytic post‐transplant lymphoproliferative disorder: a case series of nine patients

Transplant international, 2013-06, Vol.26 (6), p.616-622

2013

Link zum Volltext

Verfügbarkeit prüfen

Blockade of Chemotaxis in Graft-versus-Host Disease

The New England journal of medicine, 2012-10, Vol.367 (17), p.1667-1668

2012

Link zum Volltext

Verfügbarkeit prüfen

Unrelated donors are associated with improved relapse‐free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation

American journal of hematology, 2016-09, Vol.91 (9), p.883-887

2016

Link zum Volltext

Verfügbarkeit prüfen

Acute Cholecystitis Is a Common Complication after Allogeneic Stem Cell Transplantation and Is Associated with the Use of Total Parenteral Nutrition

Biology of blood and marrow transplantation, 2015-04, Vol.21 (4), p.768-771

2015

Link zum Volltext

Verfügbarkeit prüfen

Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI

American journal of hematology, 2016-04, Vol.91 (4), p.426-429

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 34

Suche als RSS-Feed

Aktive Filter

KollektionEbook Central Perpetual and DDA

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Humans
(32)
Life Sciences & Biomedicine
(31)
Male
(30)
Middle Aged
(27)
Adult
(25)
Aged
(25)
Hematology
(17)
Transplantation
(15)
Young Adult
(15)
Hematopoietic Stem Cell Transplantation - Adverse Effects
(14)
Hematopoietic Stem Cell Transplantation - Methods
(13)
Graft Vs Host Disease - Prevention & Control
(12)
Treatment Outcome
(11)
Transplantation, Homologous
(10)
Adolescent
(9)
Retrospective Studies
(9)
Immunology
(8)
Recurrence
(8)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease

Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation

Ezh2 phosphorylation state determines its capacity to maintain CD8 + T memory precursors for antitumor immunity

Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis

Post-transplant lymphoproliferative disorder after lung transplantation: A review of 35 cases

Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen–specific CD8+ T Cells After Allogeneic Stem Cell Transplantation

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation

Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation

Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning

Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients

Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research

Pilot Study of Prophylactic Ex Vivo Costimulated Donor Leukocyte Infusion After Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation

Plasmacytic post‐transplant lymphoproliferative disorder: a case series of nine patients

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

Blockade of Chemotaxis in Graft-versus-Host Disease

Unrelated donors are associated with improved relapse‐free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation

Acute Cholecystitis Is a Common Complication after Allogeneic Stem Cell Transplantation and Is Associated with the Use of Total Parenteral Nutrition

Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI

Aktive Filter

Suchergebnisse filtern